Novel metals and metal complexes as platforms for cancer therapy.

Metals are essential cellular components selected by nature to function in several indispensable biochemical processes for living organisms. Metals are endowed with unique characteristics that include redox activity, variable coordination modes, and reactivity towards organic substrates. Due to their reactivity, metals are tightly regulated under normal conditions and aberrant metal ion concentrations are associated with various pathological disorders, including cancer. For these reasons, coordination complexes, either as drugs or prodrugs, become very attractive probes as potential anticancer agents. The use of metals and their salts for medicinal purposes, from iatrochemistry to modern day, has been present throughout human history. The discovery of cisplatin, cis-[Pt(II) (NH(3))(2)Cl(2)], was a defining moment which triggered the interest in platinum(II)- and other metal-containing complexes as potential novel anticancer drugs. Other interests in this field address concerns for uptake, toxicity, and resistance to metallodrugs. This review article highlights selected metals that have gained considerable interest in both the development and the treatment of cancer. For example, copper is enriched in various human cancer tissues and is a co-factor essential for tumor angiogenesis processes. However the use of copper-binding ligands to target tumor copper could provide a novel strategy for cancer selective treatment. The use of nonessential metals as probes to target molecular pathways as anticancer agents is also emphasized. Finally, based on the interface between molecular biology and bioinorganic chemistry the design of coordination complexes for cancer treatment is reviewed and design strategies and mechanisms of action are discussed.

Small molecule modulators of copper-induced Abeta aggregation.

Our design of bifunctional metal chelators as chemical probes and potential therapeutics for Alzheimer's disease (AD) is based on the incorporation of a metal binding moiety into structural frameworks of Abeta aggregate-imaging agents. Using this strategy, two compounds 2-[4-(dimethylamino)phenyl]imidazo[1,2-a]pyridine-8-ol (1) and N(1),N(1)-dimethyl-N(4)-(pyridin-2-ylmethylene)benzene-1,4-diamine (2) were prepared and characterized. The bifunctionality for metal chelation and Abeta interaction of 1 and 2 was verified by spectroscopic methods. Furthermore, the reactivity of 1 and 2 with Cu(II)-associated Abeta aggregates was investigated. The modulation of Cu(II)-triggered Abeta aggregation by 1 and 2 was found to be more effective than that by the known metal chelating agents CQ, EDTA, and phen. These studies suggest a new class of multifunctional molecules for the development of chemical tools to unravel metal-associated events in AD and potential therapeutic agents for metal-ion chelation therapy.

Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.

Amyloid-beta (Abeta) plaques are largely associated with the neuropathogenesis of Alzheimer's disease (AD). Metal ions such as Cu(II) and Zn(II) have been implicated as contributors to their formation and deposition. Metal chelators have been used to modulate metal-induced Abeta aggregation. The bidentate ligand clioquinol (CQ) presents an effective influence on metal-involved Abeta aggregation, which has been explained through its metal chelation and is generally monitored by fluorescence and turbidity assays in vitro. The studies herein, however, suggest that the effects of CQ on metal-driven Abeta aggregation may not be visualized accurately by both assays. Subsequently, the present work demonstrates that CQ is able to chelate metal ions from metal-Abeta species and to assist, in part, in the disaggregation of Abeta aggregates, but it could not completely hinder the progression of Abeta aggregation.

Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

In this study, we compare the proteasome inhibition capabilities of two anticancer candidates, [Ni(L(IA))(2)] (1) and [Zn(L(IA))(2)] (2), where L(IA-) is the deprotonated form of the ligand 2,4-diiodo-6-(((2-pyridinylmethyl)amino)methyl)phenol. Species 1 contains nickel(II), a considerably inert ion that favors covalency, whereas 2 contains zinc(II), a labile transition metal ion that favors predominantly ionic bonds. We report on the synthesis and characterization of 1 and 2 using various spectroscopic, spectrometric, and structural methods. Furthermore, the pharmacological effects of 1 and 2, along with those of the salts NiCl(2) and ZnCl(2), were evaluated in vitro and in cultured human cancer cells in terms of their proteasome-inhibitory and apoptotic cell-death-inducing capabilities. It is shown that neither NiCl(2) nor 1 have the ability to inhibit the proteasome activity at any sustained levels. However, ZnCl(2) and 2 showed superior inhibitory activity versus the chymotrypsin-like activity of both the 26S proteasome (IC(50) = 5.7 and 4.4 micromol/L, respectively) and the purified 20S proteasome (IC(50) = 16.6 and 11.7 micromol/L, respectively) under cell-free conditions. Additionally, inhibition of proteasomal activity in cultured prostate cancer cells by 2 was associated with higher levels of ubiquitinated proteins and apoptosis. Treatment with either the metal complex or the salt was relatively nontoxic toward human normal cells. These results strengthen the current working hypothesis that fast ligand dissociation is required to generate an [ML(IA)](+) pharmacophore, capable of interaction with the proteasome. This interaction, possibly via N-terminal threonine amino acids present in the active sites, renders the proteasome inactive. Our results present a compelling rationale for 2 along with its gallium(III) and copper(II) congeners to be further investigated as potential anticancer drugs that act as proteasome inhibitiors.

Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome.

Selective 20S proteasomal inhibition and apoptosis induction were observed when several lines of cancer cells were treated with a series of copper complexes described as [Cu(L(I))Cl] (1), [Cu(L(I))OAc] (2), and [Cu(HL(I))(L(I))]OAc (3), where HL(I) is the ligand 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol. These complexes were synthesized, characterized by means of ESI spectrometry, infrared, UV-visible and EPR spectroscopies, and X-ray diffraction when possible. After full characterization species 1-3 were evaluated for their ability to function as proteasome inhibitors and apoptosis inducers in C4-2B and PC-3 human prostate cancer cells and MCF-10A normal cells. With distinct stoichiometries and protonation states, this series suggests the assignment of species [CuL(I)](+) as the minimal pharmacophore needed for proteasomal chymotryspin-like activity inhibition and permits some initial inference of mechanistic information.

Synthesis, redox, and amphiphilic properties of responsive salycilaldimine-copper(II) soft materials.

Hydrolysis of the asymmetric pyridine- and phenol-containing ligand HL (1) (2-hydroxy-4-6-di- tert-butylbenzyl-2-pyridylmethyl)imine) led to the use of bis-(3,5-di -tert-butyl-2-phenolato-benzaldehyde)copper(II), [Cu (II)(L (SAL)) 2] ( 1) as a precursor for bis-(2,4-di- tert-butyl-6-octadecyliminomethyl-phenolato)copper(II), [Cu (II)(L (2)) 2] ( 3), bis-(2,4-di- tert-butyl-6-octadecyl aminomethyl-phenolato)copper(II), [Cu (II)(L (2A)) 2] ( 3'), and bis-(2,4-di- tert-butyl-6-[(3,4,5-tris-dodecyloxy-phenylimino)-methyl]-phenolato)copper(II), [Cu (II)(L (3)) 2] ( 4). These complexes exhibit hydrophilic copper-containing head groups, hydrophobic alkyl and alkoxo tails, and present potential as precursors for redox-responsive Langmuir-Blodgett films. All systems were characterized by means of elemental, spectrometric, spectroscopic, and electrochemical techniques, and their amphiphilic properties were probed by means of compression isotherms and Brewster angle microscopy. Good redox activity was observed for 3 with two phenoxyl radical processes between 0.5 and 0.8 V vs Fc (+)/Fc, but this complex lacks amphiphilic behavior. To attain good balance between redox response and amphiphilicity, increased core flexibility in 3' and incorporation of alkoxy chains in 4 were attempted. Film formation with collapse at 14 mN.m (-1) was observed for the alkoxy-derivative but redox-response was seriously compromised. Core flexibility improved Langmuir film formation with a higher formal collapse and showed excellent cyclability of the ligand-based processes.

Amphiphilic and magnetic properties of a new class of cluster-bearing [L2Cu4(mu4-O)(mu2-carboxylato)4] soft materials.

A general approach toward amphiphilic systems bearing multimetallic clusters and their ability to form Langmuir-Blodgett films is presented. The synthetic strategy to stabilize these clusters involves the use of a ligand (HL) containing an N(2)O-donor set and long octadecanoic chains to obtain the carboxylate-supported [L(2)Cu(4)(mu(4)-O)(mu(2)-OAc)(4)]EtOH (1) and [L(2)Cu(4)(mu(4)-O)(mu(2)-OBz)(4)] (2) in which OAc(-) and OBz(-) represent acetate (1) and benzoate (2) co-ligands. These species were thoroughly characterized and had their structures solved by X-ray crystallography. We observed that the mu-oxo Cu(4) cluster is antiferromagnetically coupled and used broken-symmetry density functional theory (DFT) calculations to describe the main superexchange pathways of the tetracopper core. We also describe the amphiphilic properties of the ligand and the cluster-containing systems by means of area versus pressure isotherms and show that these cluster-bearing species can be transferred onto solid substrates yielding homogeneous Langmuir-Blodgett films, as characterized by atomic force microscopy and contact angle measurements.

Archetypical modeling and amphiphilic behavior of cobalt(II)-containing soft-materials with asymmetric tridentate ligands.

The stabilization of a bivalent oxidation state in cobalt complexes of phenolate-based asymmetric tridentate ligands with iodo and bromo substituents is studied. The complexes [CoII(LIA)2].2CH3OH (1) and [CoII(LBrA)2].CH3OH (2) were characterized by means of several spectroscopic and spectrometric techniques. The molecular structure of 1 was determined by diffractometric analysis and reveals the cobalt(II) ion in a distorted-octahedral geometry. The centrosymmetric metal ion adopts a local D2h symmetry and is surrounded by facially coordinated ligands. Equivalent donor sets in both ligands are trans to each other, and DFT calculations suggest that the fac-trans configuration is favored by a small margin when compared to the fac-cis isomers. Both DFT calculations and EPR spectroscopy agree with a high-spin S=3/2 electronic configuration given by [ag1, b1g1, ag1, b2g2, b3g2]. This oxidation state was indirectly observed by the lack of a ppiphenolate-->dsigma*cobalt(III) charge-transfer band, which is found between 430 and 470 nm for similar cobalt(III) species. On the basis of the geometrical preferences and the oxidation state of archetypical 1 and 2, two metallosurfactants [CoII(LI-ODA)2] (3) and [CoII(LI-NOBA)2].CH2Cl2 (4) were obtained. The redox chemistry of 1-4 is marked by metal- and ligand-centered activity with several follow up processes and film formation on the electrode. Both metallosurfactants exhibit amphiphilic properties and organization, as shown by compression isotherms and Brewster angle microscopy but exhibit dissimilar collapse mechanisms; whereas 3 collapses at constant pressure, 4 exhibits a constant-area collapse. Langmuir-Blodgett films are readily obtained and were characterized by equilibrium contact angle and atomic force microscopy.